Citations

Showing 10 of 108060 citations.

Percutaneous transcatheter pulmonary and tricuspid valve replacements in a patient with carcinoid heart disease
Pereyra, Milagros , Arsanjani, Reza , Arsanjani, Reza , Pereyra, Milagros , Farina, Juan M. , Chao, Chieh‐Ju

Mayo Clinic

European Heart Journal - Case Reports | October 13, 2023 | Volume: 7 | Issue: 11 | Pages: No page available

10.1093/ehjcr/ytad511 | PMID 38025127 Get It

P1.1: Laryngotracheal transplant: Patient and caregivers’ beliefs and perceptions
Grandjean, Danielle, Cotton-Zacharias, Stephanie, Weir, Isabel B. , Lott, David G. , Sharp, Richard R. , Curtis, Susan

Mayo Clinic

Transplantation | October 13, 2023 | Volume: 107 | Issue: 10S1 | Pages: 78-78

10.1097/01.tp.0000993444.58789.55 Get It

P2.3: Rapid Maastricht type 3 donors and normothermic perfusion: Relieving time constraints in non-renal organ recovery
Ruch, Brianna , Kumm, Kayla , Kirk, Wendy Van, Geraghty, P.J., Harbell, Jack W. , Aqel, Bashar , Reddy, Kunam S. , Mathur, Amit K. , Aqel, Bashar A. , Katariya, Nitin

Mayo Clinic

Transplantation | October 13, 2023 | Volume: 107 | Issue: 10S1 | Pages: 82-82

10.1097/01.tp.0000993480.41080.40 Get It

Treatment of intramedullary spinal cord tumors: a modified Delphi technique of the North American Spine Society Section of Spine Oncology
Pennington, Zach , Elsamadicy, Aladine A. , Dea, Nicolas , Desai, Atman , Gokaslan, Ziya L. , Hsu, Wesley , Krishnaney, Ajit A., Laufer, Ilya , Lo, Sheng-Fu Larry , Macki, Mohamed, Mehta, Ankit I. , Ozturk, Ali K. , Sciubba, Daniel M. , Pennington, Zach , Hersh, Andrew M. , Lubelski, Daniel , Goodwin, C. Rory , Jallo, George I. , Shin, John H. , Soliman, Hesham Magdi

Mayo Clinic

Journal of Neurosurgery: Spine | October 13, 2023 | Volume: 40 | Issue: 1 | Pages: 1-10

10.3171/2023.8.spine23190 | PMID 37856379 Get It

OBJECTIVE Intramedullary spinal cord tumors (IMSCTs) are rare tumors with heterogeneous presentations and natural histories that complicate their management. Standardized guidelines are lacking on when to surgically intervene and the appropriate aggressiveness of resection, especially given the risk of new neurological deficits following resection of infiltrative tumors. Here, the authors present the results of a modified Delphi method using input from surgeons experienced with IMSCT removal to construct a framework for the operative management of IMSCTs based on the clinical, radiographic, and tumor-specific characteristics. METHODS A modified Delphi technique was conducted using a group of 14 neurosurgeons experienced in IMSCT resection. Three rounds of written correspondence, surveys, and videoconferencing were carried out. Participants were queried about clinical and radiographic criteria used to determine operative candidacy and guide decision-making. Members then completed a final survey indicating their choice of observation or surgery, choice of resection strategy, and decision to perform duraplasty, in response to a set of patient- and tumor-specific characteristics. Consensus was defined as ≥ 80% agreement, while responses with 70%–79% agreement were defined as agreement. RESULTS Thirty-six total characteristics were assessed. There was consensus favoring surgical intervention for patients with new-onset myelopathy (86% agreement), chronic myelopathy (86%), or progression from mild to disabling numbness (86%), but disagreement for patients with mild numbness or chronic paraplegia. Age was not a determinant of operative candidacy except among frail patients, who were deemed more suitable for observation (93%). Well-circumscribed (93%) or posteriorly located tumors reaching the surface (86%) were consensus surgical lesions, and participants agreed that the presence of syringomyelia (71%) and peritumoral T2 signal change (79%) were favorable indications for surgery. There was consensus that complete loss of transcranial motor evoked potentials with a 50% decrease in the D-wave amplitude should halt further resection (93%). Preoperative symptoms seldom influenced choice of resection strategy, while a distinct cleavage plane (100%) or visible tumor-cord margins (100%) strongly favored gross-total resection. CONCLUSIONS The authors present a modified Delphi technique highlighting areas of consensus and agreement regarding surgical management of IMSCTs. Although not intended as a substitute for individual clinical decision-making, the results can help guide care of these patients. Additionally, areas of controversy meriting further investigation are highlighted.
Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors
Shatara, Margaret , Blue, Megan, Stanek, Joseph , Prevedello, Daniel M. , Giglio, Pierre , Puduvalli, Vinay K. , Wong, Kenneth , Nelson, Marvin D. , Gilles, Floyd H. , Adams, Roberta H. , Pauly, Jasmine, O’Halloran, Katrina , Dhall, Girish , Giglio, Pierre , Puduvalli, Vinay K , Dhall, Girish , Prevedello, Daniel M , Liu, Yin , Gardner, Sharon L , Allen, Jeffrey C. , Margol, Ashley , Finlay, Jonathan L.

Mayo Clinic

Neuro-Oncology Practice | October 13, 2023 | Volume: 11 | Issue: 2 | Pages: 188-198

10.1093/nop/npad067 | PMID 38496907 Get It

Abstract Background Patients with relapsed intracranial germinoma can achieve durable remission with standard chemotherapy regimens and/or reirradiation; however, innovative therapies are required for patients with relapsed and/or refractory intracranial nongerminomatous germ cell tumors (NGGCTs) due to their poor prognosis. Improved outcomes have been reported using reinduction chemotherapy to achieve minimal residual disease, followed by marrow-ablative chemotherapy (HDCx) with autologous hematopoietic progenitor cell rescue (AuHPCR). We conducted a phase II trial evaluating the response and toxicity of a 3-drug combination developed for recurrent intracranial germ cell tumors consisting of gemcitabine, paclitaxel, and oxaliplatin (GemPOx). Methods A total of 9 patients with confirmed relapsed or refractory intracranial GCT were enrolled after signing informed consent, and received at least 2 cycles of GemPOx, of which all but 1 had relapsed or refractory NGGCTs. One patient with progressive disease was found to have pathologically confirmed malignant transformation to pure embryonal rhabdomyosarcoma (without GCT elements), hence was ineligible and not included in the analysis. Patients who experienced sufficient responses proceeded to receive HDCx with AuHPCR. Treatment response was determined based on radiographic tumor assessments and tumor markers. Results A total of 7 patients achieved sufficient response and proceeded with HDCx and AuHPCR, and 5 subsequently received additional radiotherapy. A total of 2 patients developed progressive disease while receiving GemPOx. Myelosuppression and transaminitis were the most common treatment-related adverse events. With a mean follow-up of 44 months, 4 patients (3 NGGCTs, 1 germinoma) are alive without evidence of disease. Conclusions GemPOx demonstrates efficacy in facilitating stem cell mobilization, thus facilitating the feasibility of both HDCx and radiotherapy.
Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases
Corriveau‐Lecavalier, Nick , Barnard, Leland R , Botha, Hugo , Graff‐Radford, Jonathan , Ramanan, Vijay K. , Lee, Jeyeon , Dicks, Ellen , Rademakers, Rosa , Boeve, Bradley F. , Fields, Julie A. , Graff‐Radford, Neill R. , Knopman, David S. , Lowe, Val J. , Petersen, Ronald C. , Jack, Clifford R. , Jones, David T. , Knopman, David S. , Dickson, Dennis W , Jack, Clifford R , Jones, David T , Boeve, Brad , Botha, Hugo , Ramanan, Vijay K , Corriveau-Lecavalier, Nick , Machulda, Mary M. , Dickson, Dennis W.

Mayo Clinic

Brain | October 13, 2023 | Volume: 147 | Issue: 4 | Pages: 1483-1496

10.1093/brain/awad356 | PMID 37831661 Get It

Abstract There is a longstanding ambiguity regarding the clinical diagnosis of dementia syndromes predominantly targeting executive functions versus behaviour and personality. This is due to an incomplete understanding of the macro-scale anatomy underlying these symptomatologies, a partial overlap in clinical features and the fact that both phenotypes can emerge from the same pathology and vice versa. We collected data from a patient cohort of which 52 had dysexecutive Alzheimer’s disease, 30 had behavioural variant frontotemporal dementia (bvFTD), seven met clinical criteria for bvFTD but had Alzheimer’s disease pathology (behavioural Alzheimer’s disease) and 28 had amnestic Alzheimer’s disease. We first assessed group-wise differences in clinical and cognitive features and patterns of fluorodeoxyglucose (FDG) PET hypometabolism. We then performed a spectral decomposition of covariance between FDG-PET images to yield latent patterns of relative hypometabolism unbiased by diagnostic classification, which are referred to as ‘eigenbrains’. These eigenbrains were subsequently linked to clinical and cognitive data and meta-analytic topics from a large external database of neuroimaging studies reflecting a wide range of mental functions. Finally, we performed a data-driven exploratory linear discriminant analysis to perform eigenbrain-based multiclass diagnostic predictions. Dysexecutive Alzheimer’s disease and bvFTD patients were the youngest at symptom onset, followed by behavioural Alzheimer’s disease, then amnestic Alzheimer’s disease. Dysexecutive Alzheimer’s disease patients had worse cognitive performance on nearly all cognitive domains compared with other groups, except verbal fluency which was equally impaired in dysexecutive Alzheimer’s disease and bvFTD. Hypometabolism was observed in heteromodal cortices in dysexecutive Alzheimer’s disease, temporo-parietal areas in amnestic Alzheimer’s disease and frontotemporal areas in bvFTD and behavioural Alzheimer’s disease. The unbiased spectral decomposition analysis revealed that relative hypometabolism in heteromodal cortices was associated with worse dysexecutive symptomatology and a lower likelihood of presenting with behaviour/personality problems, whereas relative hypometabolism in frontotemporal areas was associated with a higher likelihood of presenting with behaviour/personality problems but did not correlate with most cognitive measures. The linear discriminant analysis yielded an accuracy of 82.1% in predicting diagnostic category and did not misclassify any dysexecutive Alzheimer’s disease patient for behavioural Alzheimer’s disease and vice versa. Our results strongly suggest a double dissociation in that distinct macro-scale underpinnings underlie predominant dysexecutive versus personality/behavioural symptomatology in dementia syndromes. This has important implications for the implementation of criteria to diagnose and distinguish these diseases and supports the use of data-driven techniques to inform the classification of neurodegenerative diseases.
Commentary: Microvascular Decompression for Treatment of Simultaneous Arterial and Venous Conflict Causing Trigeminal Neuralgia: 2-Dimensional Operative Video
Eghlimi, Ryan , Meyer, Jenna H., Bendok, Bernard R. , Zimmerman, Richard S. , Eghlimi, Ryan A, Bendok, Bernard R

Mayo Clinic

Operative Neurosurgery | October 13, 2023 | Volume: 25 | Issue: 6 | Pages: e380-e381

10.1227/ons.0000000000000937 | PMID 37831982 Get It

Editorial: Faecal microbiota transplantation in IBS—Moving closer or away from success?
Lesmana, Elvira , Grover, Madhusudan

Mayo Clinic

Alimentary Pharmacology & Therapeutics | October 13, 2023 | Volume: 58 | Issue: 9 | Pages: 950-951

10.1111/apt.17724 | PMID 37831529 Get It

LINKED CONTENTThis article is linked to Yau et al papers. To view these articles, visit https://doi.org/10.1111/apt.17703 and https://doi.org/10.1111/apt.17729
Weight-Bearing CT with Maximum Ankle Dorsiflexion to Identify Impingement and Tibial Plafond Stress Fracture
Brown, Parker J. , Wyse, Aaron , Long, Jeremiah R. , Long, Jeremiah , Patel, Karan A.

Mayo Clinic

JBJS Case Connector | October 13, 2023 | Volume: 13 | Issue: 4 | Pages: No page available

10.2106/jbjs.cc.23.00356 | PMID 37831806 Get It

Case: A 25-year-old male pole vaulter presented with several months of right ankle pain. Radiographs showed an anterior tibial osteophyte with a small intra-articular body suggesting impingement. Weight-bearing computed tomography (CT) revealed an associated tibial plafond stress fracture. Subsequent arthroscopy with osteophyte resection and loose body removal significantly improved symptoms, and he gradually resumed training. Conclusion: Stress fractures should always be considered in athletes with ankle pain. A unique aspect of this case was the use of weight-bearing CT in diagnosis and surgical planning. To our knowledge, this is the first described case in which weight-bearing CT was used in this fashion.
Abstract P3160: Myocarditis Treatments Within Our Sights: Targeting Inflammatory Conversations In The Heart Using Extracellular Vesicles
Wolfram, Joy , Wolfram, Joy , Beetler, Danielle J. , Bruno, Katelyn A. , Fairweather, DeLisa

Mayo Clinic

Circulation Research | October 13, 2023 | Volume: 133 | Issue: Suppl_1 | Pages: No page available

10.1161/res.133.suppl_1.p3160 Get It

Viral myocarditis is an inflammatory cardiomyopathy with no pharmacologic agent currently able to quell the immune mechanisms that damage the heart in their inflammatory crossfire to quell infections, without risk of immunocompromise. Sex differences are well known in inflammatory and/or infectious diseases. Females display more efficient, anti-inflammatory responses to external threats like viruses, while males launch a pro-inflammatory defensive response. Myocarditis is a classic case of an infectious, inflammatory disease being more frequent and more severe in men, while pre-menopausal women are most protected. Extracellular vesicles are biocompatible, highly abundant, stable messaging carriers with no transformative risk, and hold great promise as therapeutics due to their functional cargo. As EVs are soluble mediators of the conversations between cells, we seek to redirect protective anti-inflammatory messaging from pre-menopausal women to male mice, using a highly translational model of murine myocarditis. We derive EVs from omental fat, repurposing this source to derive a purified, therapeutic component. Our results show robust immune system control, with EV treatments effectively attenuating pro-inflammatory inflammasome and complement markers, while leaving regulatory components like M2b macrophages and complement component CR1 unchanged. Treated mice are healthier during acute disease and demonstrate better heart function than control mice, despite being a strain susceptible to myocarditis and subsequent dilated cardiomyopathy. Tests using EVs from similarly aged men do not demonstrate this anti-inflammatory capacity. Proteomic and RNA-sequencing content comparisons of these EVs from these two donor groups reveal important proteins and regulatory micro RNAs. Our data suggest that EVs from fat may be a novel anti-inflammatory treatment for viral myocarditis, however individual donors show varying therapeutic capacity, with EV content heavily influenced by sex and age. This study not only addresses a major therapeutic gap in the myocarditis field, but also provides functional and -omic based comparisons of EVs from donors differing only by sex, to test if female cardioprotection from myocarditis is transferrable.